Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.43 |
| ▸ | NEK2 | P51955 | 6/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16786559 | 1.00 | BTK (0.43) | BTKNEK2RETACACBRPS6KB1 | |
| SCHEMBL16786558 | 1.00 | BTK (0.43) | BTKNEK2RETACACBRPS6KB1 | |
| SCHEMBL16765220 | 1.00 | BTK (0.43) | BTKNEK2RETACACBRPS6KB1 | |
| SCHEMBL16786567 | 1.00 | BTK (0.43) | BTKNEK2RETACACBRPS6KB1 | |
| SCHEMBL16786557 | 0.89 | BTK (0.41) | BTKRETACACB | |
| SCHEMBL16786552 | 0.89 | BTK (0.41) | BTKRETACACB | |
| SCHEMBL25668037 | 0.86 | NEK2 (0.49) | BTKNEK2RETACACB | |
| SCHEMBL25667215 | 0.83 | BTK (0.38) | BTKRETACACB | |
| SCHEMBL25667210 | 0.83 | BTK (0.38) | BTKRETACACB | |
| SCHEMBL16681131 | 0.82 | BTK (0.48) | BTKRETRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017155-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| EP-3753934-A1 | PYRIMIDINYL DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-2858499-B1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | BIOGEN MA INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9944622-B2 | Pyrimidinyl tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017155-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | BTK 2/4885NEK2 324/4885RET 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.